Chardan Capital Reiterates “Buy” Rating for Intellia Therapeutics (NASDAQ:NTLA)

Chardan Capital reissued their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Friday,Benzinga reports. Chardan Capital currently has a $68.00 price target on the stock.

Several other brokerages have also issued reports on NTLA. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $9.00 price target on shares of Intellia Therapeutics in a report on Friday, February 28th. Barclays lowered their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Oppenheimer cut their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Wells Fargo & Company decreased their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, Citigroup upped their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $36.47.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $8.12 on Friday. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.18. The company has a market capitalization of $841.09 million, a PE ratio of -1.49 and a beta of 2.33. The business has a fifty day moving average price of $8.13 and a two-hundred day moving average price of $11.06.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. Intellia Therapeutics’s quarterly revenue was down 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.12) EPS. Sell-side analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently added to or reduced their stakes in NTLA. GF Fund Management CO. LTD. purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $25,000. Sterling Capital Management LLC increased its position in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares during the last quarter. Harbour Investments Inc. raised its stake in Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after purchasing an additional 2,264 shares in the last quarter. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $40,000. Finally, Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $43,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.